Status:
COMPLETED
Macrophage Phenotype in Type 2 Diabetics After Myocardial Infarction and the Potential Role of miRNAs Secreted
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
DIABETES
MYOCARD INFARCTUS
Eligibility:
MALE
65-100 years
Phase:
NA
Brief Summary
The prevalence of type 2 diabetes is growing steadily. Patients with diabetes, cardiovascular complications (such as myocardial infarction (MI)) are more frequent and severe than in non-diabetic subje...
Eligibility Criteria
Inclusion
- Male Patients (to avoid the influence of estrogen hormones known to influence the M1 / M2 balance)
- Age: greater than 65 years (allowing homogeneity of the study population vis-à-vis the effect of age on differentiation M1 / M2)
- Patients hospitalized for a heart attack (chest pain, characteristic ECG changes, increased troponin levels (\> 0.06 ng / ml))
- BMI between 19 and 30 (to avoid interference of obesity per se)
- Signed informed consent
- Affiliation to a social security scheme
- Additional inclusion criterion for the group of diabetic subjects:
- HbA1c of less than 2 months between 6 and 10% (to avoid confounding effects of anti-diabetic drugs).
Exclusion
- Patients treated with anti-inflammatory agents (nonsteroidal anti-inflammatory drugs in the long term, corticosteroids, steroids, immunomodulators or immunosuppressants)
- Patients with acute inflammatory condition (in particular infectious)
- Patients with chronic inflammatory diseases (eg rheumatoid arthritis)
- Vulnerable Patients (convicts, under guardianship)
Key Trial Info
Start Date :
October 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02768935
Start Date
October 30 2017
End Date
May 24 2021
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France, 06000